EcoR1 Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

EcoR1 Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-35,301	Closed	-$484K	–	38
2017 Q1	$484K	Sell	35,301 -238,561	-87%	-$2.48M	0.12%	29
2016 Q4	$1.96M	Sell	273,862 -83,503	-23%	-$915K	0.63%	21
2016 Q3	$5.42M	Hold	357,365	–	–	1.66%	18
2016 Q2	$3.52M	Sell	357,365 -153,464	-30%	-$2.1M	1.39%	20
2016 Q1	$6.8M	Buy	+510,829	New	+$6.42M	2.38%	19

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EcoR1 Capital's SNDX Position: Q2 2017 in Review

EcoR1 Capital sold out of Syndax Pharmaceuticals (SNDX) in Q2 2017, closing a stake of 35,301 shares — an estimated $484K sold.

EcoR1 Capital first reported a position in SNDX in Q1 2016 and held it in 5 quarters. The position peaked at $6.8M in Q1 2016. 66 funds tracked by Wall St. Rank hold SNDX as of Q2 2017.

EcoR1 Capital reported no remaining Syndax Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
EcoR1 Capital sold 35,301 Syndax Pharmaceuticals shares in Q2 2017, an estimated $484K.
EcoR1 Capital first reported a position in Syndax Pharmaceuticals in Q1 2016 and held it in 5 quarters.
EcoR1 Capital's Syndax Pharmaceuticals position peaked at $6.8M in Q1 2016.
66 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2017.

Based on EcoR1 Capital's 13F filing for Q2 2017, filed 14 Aug 2017.